A study published in July 2020 found that patients with thyroid cancer who have undergone treatment such as surgery, with or without radioiodine, are not considered to be at higher risk for viral infection, including from SARS-CoV-2.
Guidance from the Thyroid Cancer Forum UK, the Society for Endocrinology, and the British Thyroid Association states that patients on suppressive doses of thyroxine should continue on their current dose. Suppressive doses of levothyroxine do not increase the risk for COVID-19 infection. However, patients who are receiving multikinase inhibitors or chemotherapy are at increased risk for severe COVID-19 and should take extra precautions.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Elwyn C. Cabebe. Fast Five Quiz: Thyroid Cancer Practice Essentials - Medscape - Oct 01, 2020.